BioCentury | Jul 20, 2019
Clinical News

July 19 Clinical Quick Takes: Polyphor closes Phase III murepavadin trials; plus Takeda and Alector

...restored normal PGRN levels in FTD patients. The data were presented Wednesday at the 2019 Alzheimer's Association...
BioCentury | Jul 27, 2018
Clinical News

Biogen, Eisai's elenbecestat reduces plaques, slows AD progression in Phase II

...MCI) or mild to moderate dementia due to Alzheimer's disease. Data were presented at the Alzheimer's Association...
...Phase II data Milestone: NA Chris Lieu elenbecestat (E2609) Biogen Inc. Eisai Co. Ltd. Beta-site APP-cleaving enzyme 1 (BACE1) Alzheimer's disease (AD) Alzheimer's Association...
BioCentury | Jul 27, 2018
Clinical News

Biogen, Eisai's BAN2401 slows cognitive decline by 30% in Phase II Alzheimer's trial

...Ltd. (Tokyo:4523) and Biogen Inc. (NASDAQ:BIIB) presented highly anticipated detailed results for BAN2401 at the Alzheimer's Association...
...in brain amyloid levels Status: Additional Phase II data Milestone: NA Erin McCallister BAN2401 Biogen Inc. Eisai Co. Ltd. Beta amyloid Alzheimer's Association's...
BioCentury | Jul 25, 2018
Clinical News

BAN2401 slows cognitive decline by 30% in Phase II Alzheimer's trial

...Tokyo:4523) and Biogen Inc. (NASDAQ:BIIB) presented highly anticipated detailed results for BAN2401 Wednesday at the Alzheimer's Association...
...BioArctic AB (SSE:BIOA B), which lost SEK6 to SEK151 on Wednesday. Erin McCallister BAN2401 Biogen Inc. Eisai Co. Ltd. Beta amyloid Alzheimer's Association's...
BioCentury | Feb 16, 2018
Clinical News

Boehringer discontinues PDE-9A inhibitor for AD

...week 12 vs. placebo. Boehringer plans to present full data from the trials at the Alzheimer's Association...
BioCentury | Feb 9, 2018
Clinical News

Boehringer discontinues PDE-9A inhibitor for AD

...week 12 vs. placebo. Boehringer plans to present full data from the trials at the Alzheimer's Association...
BioCentury | Jul 27, 2016
Clinical News

TauRx's LMTX fails in Phase III AD study

...of the study's patients were receiving LMTX as monotherapy. The TRx-237-015 data were presented at Alzheimer's Association...
BioCentury | Sep 14, 2015
Politics, Policy & Law

IPR battles

...misuse of the IPR proceedings." Companies and Institutions Mentioned Acorda Therapeutics Inc. (NASDAQ:ACOR), Ardsley, N.Y. Alzheimer's Association...
...As of Sept. 3, at least 100 patient groups had signed the letter, including the Alzheimer's Association...
BioCentury | Jul 24, 2015
Clinical News

Lilly study links Amyvid to changes in treatment

...management (see BioCentury, Feb. 4, 2013) . Data from Lilly's trial were presented at the Alzheimer's Association...
...plan to conduct its own CMS-approved CED study. In response to CMS's CED policy, the Alzheimer's Association...
BioCentury | Jul 23, 2015
Clinical News

Lilly says solanezumab data suggest disease-modifying effect

...patients who delayed treatment by 80 weeks. In an abstract from a presentation at the Alzheimer's Association...
...of delayed-start analysis to determine the long-term efficacy and disease-modifying effects of AD treatments. The Alzheimer's Association...
Items per page:
1 - 10 of 77
BioCentury | Jul 20, 2019
Clinical News

July 19 Clinical Quick Takes: Polyphor closes Phase III murepavadin trials; plus Takeda and Alector

...restored normal PGRN levels in FTD patients. The data were presented Wednesday at the 2019 Alzheimer's Association...
BioCentury | Jul 27, 2018
Clinical News

Biogen, Eisai's elenbecestat reduces plaques, slows AD progression in Phase II

...MCI) or mild to moderate dementia due to Alzheimer's disease. Data were presented at the Alzheimer's Association...
...Phase II data Milestone: NA Chris Lieu elenbecestat (E2609) Biogen Inc. Eisai Co. Ltd. Beta-site APP-cleaving enzyme 1 (BACE1) Alzheimer's disease (AD) Alzheimer's Association...
BioCentury | Jul 27, 2018
Clinical News

Biogen, Eisai's BAN2401 slows cognitive decline by 30% in Phase II Alzheimer's trial

...Ltd. (Tokyo:4523) and Biogen Inc. (NASDAQ:BIIB) presented highly anticipated detailed results for BAN2401 at the Alzheimer's Association...
...in brain amyloid levels Status: Additional Phase II data Milestone: NA Erin McCallister BAN2401 Biogen Inc. Eisai Co. Ltd. Beta amyloid Alzheimer's Association's...
BioCentury | Jul 25, 2018
Clinical News

BAN2401 slows cognitive decline by 30% in Phase II Alzheimer's trial

...Tokyo:4523) and Biogen Inc. (NASDAQ:BIIB) presented highly anticipated detailed results for BAN2401 Wednesday at the Alzheimer's Association...
...BioArctic AB (SSE:BIOA B), which lost SEK6 to SEK151 on Wednesday. Erin McCallister BAN2401 Biogen Inc. Eisai Co. Ltd. Beta amyloid Alzheimer's Association's...
BioCentury | Feb 16, 2018
Clinical News

Boehringer discontinues PDE-9A inhibitor for AD

...week 12 vs. placebo. Boehringer plans to present full data from the trials at the Alzheimer's Association...
BioCentury | Feb 9, 2018
Clinical News

Boehringer discontinues PDE-9A inhibitor for AD

...week 12 vs. placebo. Boehringer plans to present full data from the trials at the Alzheimer's Association...
BioCentury | Jul 27, 2016
Clinical News

TauRx's LMTX fails in Phase III AD study

...of the study's patients were receiving LMTX as monotherapy. The TRx-237-015 data were presented at Alzheimer's Association...
BioCentury | Sep 14, 2015
Politics, Policy & Law

IPR battles

...misuse of the IPR proceedings." Companies and Institutions Mentioned Acorda Therapeutics Inc. (NASDAQ:ACOR), Ardsley, N.Y. Alzheimer's Association...
...As of Sept. 3, at least 100 patient groups had signed the letter, including the Alzheimer's Association...
BioCentury | Jul 24, 2015
Clinical News

Lilly study links Amyvid to changes in treatment

...management (see BioCentury, Feb. 4, 2013) . Data from Lilly's trial were presented at the Alzheimer's Association...
...plan to conduct its own CMS-approved CED study. In response to CMS's CED policy, the Alzheimer's Association...
BioCentury | Jul 23, 2015
Clinical News

Lilly says solanezumab data suggest disease-modifying effect

...patients who delayed treatment by 80 weeks. In an abstract from a presentation at the Alzheimer's Association...
...of delayed-start analysis to determine the long-term efficacy and disease-modifying effects of AD treatments. The Alzheimer's Association...
Items per page:
1 - 10 of 77